Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$5.06 USD
-0.15 (-2.88%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $5.05 -0.01 (-0.20%) 6:54 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Cytek Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 193 | 164 | 128 | 93 | NA |
Cost Of Goods | 84 | 63 | 49 | 41 | NA |
Gross Profit | 109 | 101 | 79 | 52 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 137 | 103 | 70 | 38 | 0 |
Income After Depreciation & Amortization | -28 | -2 | 9 | 14 | 0 |
Non-Operating Income | 14 | 6 | -1 | 1 | NA |
Interest Expense | 2 | 3 | 2 | 0 | NA |
Pretax Income | -16 | 1 | 6 | 14 | NA |
Income Taxes | -4 | -1 | 3 | -5 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -12 | 2 | 3 | 19 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -12 | 3 | 3 | 19 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | 4 | 10 | 14 | 0 |
Depreciation & Amortization (Cash Flow) | 9 | 6 | 1 | 1 | NA |
Income After Depreciation & Amortization | -28 | -2 | 9 | 14 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 135.28 | 138.56 | 81.55 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.04 | 0.03 | 0.09 | NA | NA |
Diluted Net EPS (GAAP) | -0.09 | 0.02 | 0.00 | NA | NA |
Fiscal Year end for Cytek Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 46.62 | 44.86 | 58.23 | 48.00 | 49.69 |
Cost Of Goods | 21.18 | 21.85 | 25.19 | 20.82 | 21.53 |
Gross Profit | 25.44 | 23.01 | 33.05 | 27.18 | 28.16 |
SG&A, R&D, and Dept/Amort Expenses | 33.96 | 33.75 | 33.18 | 33.60 | 37.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.52 | -10.74 | -0.13 | -6.42 | -9.13 |
Non-Operating Income | 1.48 | 2.18 | 4.64 | 2.83 | 2.94 |
Interest Expense | 0.13 | 0.44 | 0.39 | 0.60 | 0.41 |
Pretax Income | -7.19 | -8.99 | 4.11 | -4.19 | -6.60 |
Income Taxes | 3.25 | -2.82 | -1.39 | 2.27 | -2.21 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.43 | -6.17 | 5.50 | -6.46 | -4.39 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.43 | -6.17 | 5.50 | -6.46 | -4.39 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 131.44 | 130.92 | 137.58 | 136.17 | 135.92 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.05 | 0.04 | -0.03 | -0.02 |
Diluted Net EPS (GAAP) | -0.08 | -0.05 | 0.04 | -0.05 | -0.03 |